Patents by Inventor Simon Fredriksson
Simon Fredriksson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11628224Abstract: A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.Type: GrantFiled: January 12, 2018Date of Patent: April 18, 2023Assignee: GENAGON THERAPEUTICS ABInventors: Johan Erik Simon Fredriksson, Olof Andries Blokzijl
-
Publication number: 20230027467Abstract: Provided herein is a method for mapping rolling circle amplification (RCA) products that contain unique identifier sequences. The method generally involves (a) producing a complex comprising population of grid oligonucleotide molecules and a population of RCA products that each have a unique RCA product identifier sequence, wherein the grid oligonucleotides are hybridized directly or indirectly via a splint to complementary sites in the RCA products; (b) extending the grid oligonucleotide molecules that are hybridized to two RCA products to add the complements of the unique RCA product identifier sequences from the two RCA products to the grid oligonucleotide molecules; (c) sequencing the extended grid oligonucleotides; (d) analyzing the sequences to identify which pairs of unique RCA product identifier sequence complements have been added onto the grid oligonucleotides; and (e) making one or more physical maps of the immobilized RCA products using the pairs of sequences identified in (d).Type: ApplicationFiled: October 27, 2020Publication date: January 26, 2023Inventor: Simon Fredriksson
-
Patent number: 11406665Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.Type: GrantFiled: January 12, 2018Date of Patent: August 9, 2022Assignee: GENAGON THERAPEUTICS ABInventors: Johan Erik Simon Fredriksson, Olof Andries Blokzijl
-
Patent number: 10781473Abstract: The present invention provides a plurality of pairs of proximity probes, each pair being capable of binding to a different target analyte, wherein the first and second proximity probes of each pair of probes comprise universal oligonucleotides conjugated to their analyte binding moieties, and hybridised to the universal oligonucleotides are different tag oligonucleotides comprising universal complement domains common to all tag oligonucleotides and unique domains unique to each tag oligonucleotide, as well as methods for their production.Type: GrantFiled: October 21, 2016Date of Patent: September 22, 2020Assignee: OLINK PROTEOMICS ABInventors: Johan Erik Simon Fredriksson, Klas Martin Lundberg
-
Patent number: 10731206Abstract: The present invention relates to a proximity probe based detection assay (“proximity assay”) for an analyte in a sample, specifically a proximity probe extension assay (PEA), an in particular to an improvement in the method to reduce non-specific “background” signals, wherein the improvement comprises the use in such assays of a component comprising 3? exonuclease activity, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte; (b) allowing the nucleic acid domains of the proximity probes to interact with each other upon binding of said proximity probes to said analyte, wherein said interaction comprises the formation of a duplex; (c) contacting said sample with a component comprising 3? exonuclease activity; (d) extending the 3? end of at least one nucleic acid domain of said duplex to generate an extension product, whereinType: GrantFiled: September 1, 2017Date of Patent: August 4, 2020Assignee: OLINK PROTEOMICS ABInventors: Simon Fredriksson, Martin Lundberg, Anna Larsson, Emma Rennel-Dickens
-
Publication number: 20190343962Abstract: A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.Type: ApplicationFiled: January 12, 2018Publication date: November 14, 2019Inventors: Johan Erik Simon FREDRIKSSON, Olof Andries BLOKZIJL
-
Publication number: 20190328788Abstract: The invention relates to apolypeptide capable of binding to TGF-? for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-?, wherein said polypeptide is capable of inhibiting the interaction of TGF-? with the receptor CLPTM1.Type: ApplicationFiled: January 12, 2018Publication date: October 31, 2019Inventors: Johan Erik Simon FREDRIKSSON, Olof Andries BLOKZIJL
-
Publication number: 20190256592Abstract: The present invention providesabinding agent capable of binding to the extracellular domain of CLPTM1 for use in the treatment or prevention of a condition which is responsive to, or benefits from, (i) immunosuppression, (ii) the reduction or reversal of one or more pro-inflammatory cytokines or the induction of an anti-inflammatory cytokine), (iii) an increase in insulin sensitivity, or (iv) therapy with GDF15 and/or TGF-? and/or IFN?, wherein said binding agent has an EC 50 value of 1 ?g/ml or less when determined by measuring binding to membrane-permeabilised O-876 cells expressing native CLPTM1 by flow cytometry, and wherein said binding agent is not a natural ligand for CLPTM.Type: ApplicationFiled: September 15, 2017Publication date: August 22, 2019Inventors: Olof Andries BLOKZIJL, Johan Erik Simon FREDRIKSSON
-
Publication number: 20180312901Abstract: The present invention provides a plurality of pairs of proximity probes, each pair being capable of binding to a different target analyte, wherein the first and second proximity probes of each pair of probes comprise universal oligonucleotides conjugated to their analyte binding moieties, and hybridised to the universal oligonucleotides are different tag oligonucleotides comprising universal complement domains common to all tag oligonucleotides and unique domains unique to each tag oligonucleotide, as well as methods for their production.Type: ApplicationFiled: October 21, 2016Publication date: November 1, 2018Inventors: Johan Erik Simon FREDRIKSSON, Klas Martin LUNDBERG
-
Publication number: 20180282403Abstract: The present invention relates to agents for reducing the activity of GDF15 and in particular the use of such agents to treat or prevent conditions associated with elevated or unwanted levels of GDF15. The invention is based on the discovery that GDF15 binds to the receptors CLPTM1 and QRFPR and provides agents for such use in the form of binding agents capable of binding to the receptors and inhibiting the interaction between GDF15 and the receptor. Further agents include polypeptides derived from the receptors which are capable of binding to GDF15 and inhibiting its interaction with the receptors. Also provided are diagnostic methods based on detecting the interaction or an effect thereof, and cytotoxic immune cells modified to have a reduced level and/or activity of CLPTM1.Type: ApplicationFiled: July 20, 2016Publication date: October 4, 2018Inventors: Olof Andries BLOKZIJL, Johan Erik Simon FREDRIKSSON
-
Publication number: 20180100189Abstract: The present invention relates to a proximity probe based detection assay (“proximity assay”) for an analyte in a sample, specifically a proximity probe extension assay (PEA), an in particular to an improvement in the method to reduce non-specific “background” signals, wherein the improvement comprises the use in such assays of a component comprising 3? exonuclease activity, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte; (b) allowing the nucleic acid domains of the proximity probes to interact with each other upon binding of said proximity probes to said analyte, wherein said interaction comprises the formation of a duplex; (c) contacting said sample with a component comprising 3? exonuclease activity; (d) extending the 3? end of at least one nucleic acid domain of said duplex to generate an extension product, whereinType: ApplicationFiled: September 1, 2017Publication date: April 12, 2018Inventors: Simon FREDRIKSSON, Martin LUNDBERG, Anna ERIKSSON, Emma RENNEL-DICKENS
-
Patent number: 9902993Abstract: The present invention relates to a proximity probe based detection assay (“proximity assay”) for an analyte in a sample, specifically a proximity probe extension assay (PEA), an in particular to an improvement in the method to reduce non-specific “background” signals, wherein the improvement comprises the use in such assays of a hyperthermophilic polymerase, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte; (b) allowing the nucleic acid domains of the proximity probes to interact with each other upon binding of said proximity probes to said analyte, wherein said interaction comprises the formation of a duplex; (c) extending the 3? end of at least one nucleic acid domain of said duplex to generate an extension product, wherein the extension reaction comprises increasing the temperature of assay above room temperature andType: GrantFiled: January 29, 2013Date of Patent: February 27, 2018Assignee: OLINK PROTEOMICS ABInventors: Simon Fredriksson, Martin Lundberg, Anna Eriksson, Emma Rennel-Dickens
-
Patent number: 9777315Abstract: The present invention relates to a proximity probe based detection assay (“proximity assay”) for an analyte in a sample, specifically a proximity probe extension assay (PEA), an in particular to an improvement in the method to reduce non-specific “background” signals, wherein the improvement comprises the use in such assays of a component comprising 3? exonuclease activity, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte; (b) allowing the nucleic acid domains of the proximity probes to interact with each other upon binding of said proximity probes to said analyte, wherein said interaction comprises the formation of a duplex; (c) contacting said sample with a component comprising 3? exonuclease activity; (d) extending the 3? end of at least one nucleic acid domain of said duplex to generate an extension product, whereinType: GrantFiled: January 30, 2012Date of Patent: October 3, 2017Assignee: OLINK PROTEOMICS ABInventors: Simon Fredriksson, Martin Lundberg, Anna Eriksson, Emma Rennel-Dickens
-
Patent number: 9677131Abstract: The present invention relates to the use of a conjugate of a non-analyte-specific binding protein coupled to a nucleic acid as a blocking reagent in a probe-based detection assay, which uses a probe comprising a proteinaceous analyte-binding partner coupled to a nucleic acid domain to detect an analyte in a sample.Type: GrantFiled: July 13, 2011Date of Patent: June 13, 2017Assignee: OLINK PROTEOMICS ABInventors: Simon Fredriksson, Bonnie Tran
-
Patent number: 9657339Abstract: A method for amplifying a target nucleic acid is disclosed, which includes: (a) fragmenting a nucleic acid sample to create a target fragment comprising a target nucleic acid and two probe-complementary portions; (b) contacting said fragmented nucleic acid sample with a probe comprising two target fragment-complementary portions complementary to the probe-complementary portions of the target fragment; (c) rendering the fragmented nucleic acid sample single-stranded; (d) allowing the probe-complementary portions to hybridise with the target-fragment complementary portions; (e) if the probe in step (b) is not immobilised, immobilising the probe-target fragment hybrid on a solid phase via immobilisation moiety; (f) separating non-immobilised nucleic acid fragments from the solid phase; (g) contacting the solid phase with a ligase to ligate ligatable 5? and 3? ends of the target fragment whereby the target fragment is circularized; and (h) amplifying said circularized target fragment.Type: GrantFiled: December 3, 2010Date of Patent: May 23, 2017Assignee: Agilent Technologies, Inc.Inventors: Fredrik Roos, Henrik Johansson, Magnus Isaksson, Mats Nilsson, Olle (Olof) Ericsson, Simon Fredriksson
-
Publication number: 20150044674Abstract: The present invention relates to a proximity probe based detection assay (“proximity assay”) for an analyte in a sample, specifically a proximity probe extension assay (PEA), an in particular to an improvement in the method to reduce non-specific “background” signals, wherein the improvement comprises the use in such assays of a hyperthermophilic polymerase, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte; (b) allowing the nucleic acid domains of the proximity probes to interact with each other upon binding of said proximity probes to said analyte, wherein said interaction comprises the formation of a duplex; (c) extending the 3? end of at least one nucleic acid domain of said duplex to generate an extension product, wherein the extension reaction comprises increasing the temperature of assay above room temperature andType: ApplicationFiled: January 29, 2013Publication date: February 12, 2015Applicant: Olink ABInventors: Simon Fredriksson, Martin Lundberg, Anna Eriksson, Emma Rennel-Dickens
-
Publication number: 20140106361Abstract: Methods and compositions for detecting an analyte in a sample are provided. In practicing the subject methods, a sample is combined with at least a pair of proximity probes that each include an analyte binding domain and a nucleic acid domain. The resultant mixture is then contacted with a pair of asymmetric nucleic acid connectors. Proximity dependent connector mediated interaction between the nucleic acid domains of the proximity probes is then detected to determine the presence of the analyte in the sample. Also provided are kits and systems for practicing the subject methods.Type: ApplicationFiled: November 11, 2013Publication date: April 17, 2014Inventors: Simon Fredriksson, Ronald W. Davis
-
Publication number: 20140030721Abstract: The present invention relates to a proximity probe based detection assay (“proximity assay”) for an analyte in a sample, specifically a proximity probe extension assay (PEA), an in particular to an improvement in the method to reduce non-specific “background” signals, wherein the improvement comprises the use in such assays of a component comprising 3? exonuclease activity, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte; (b) allowing the nucleic acid domains of the proximity probes to interact with each other upon binding of said proximity probes to said analyte, wherein said interaction comprises the formation of a duplex; (c) contacting said sample with a component comprising 3? exonuclease activity; (d) extending the 3? end of at least one nucleic acid domain of said duplex to generate an extension product, whereinType: ApplicationFiled: January 30, 2012Publication date: January 30, 2014Applicant: OLINK ABInventors: Simon Fredriksson, Martin Lundberg, Anna Eriksson, Emma Rennel-Dickens
-
Patent number: D870478Type: GrantFiled: April 13, 2017Date of Patent: December 24, 2019Assignee: Flexibod LimitedInventors: Damien Gerard Mason, James Robert Lynch, Mathew Gill Bates, Simon Fredriksson
-
Patent number: D897707Type: GrantFiled: January 24, 2018Date of Patent: October 6, 2020Assignee: Flexibod LimitedInventors: Damien Gerard Mason, James Robert Lynch, Mathew Gill Bates, Simon Fredriksson, Brian Joseph Garvey